

## **MSD COMMENT ON STATEMENT OF OBJECTIONS ISSUED BY THE COMPETITION AND MARKETS AUTHORITY**

**Hoddesdon, UK, 23 May 2017** – MSD has received a Statement of Objections from the UK Competition and Markets Authority (CMA) setting out its provisional findings relating to discounts offered by MSD on sales of a pharmaceutical product, Remicade (*infliximab*). MSD is cooperating fully with the CMA's ongoing investigation.

MSD is confident that the proceedings will show that MSD has complied with competition law at all times. The discounts in question meant that infliximab was competitively priced and offered savings to the UK National Health Service, without hindering competition. The Statement of Objections sets out the CMA's provisional views only – it is not a finding that MSD has infringed competition law and MSD welcomes the opportunity to respond.

As a company whose products touch the lives and wellbeing of people around the world, we are committed to the highest standards of ethics and integrity.

We have no further comment at this stage.

-Ends-

### **Contact:**

Meral Nugent (MSD)

01992 452358 / 07884 232042

[meral.nugent@merck.com](mailto:meral.nugent@merck.com)

### **Notes to editors:**

#### **About MSD**

For more than a century, MSD, a leading global biopharmaceutical company, has been inventing for life, bringing forward medicines and vaccines for the world's most challenging diseases. MSD is a tradename of Merck & Co., Inc., with headquarters in Kenilworth, N.J., U.S.A. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions.

For more information, visit [www.msd-UK.com](http://www.msd-UK.com) and connect with us on Twitter @MSDintheUK.